培美曲塞联合铂类治疗非小细胞肺癌的Meta分析

Pemetrexed plus platinum in non-small cell lung cancer:a Meta analysis of randomized controlled trials

目的本研究旨在对培美曲塞或吉西他滨联合铂类治疗非小细胞肺癌的疗效和安全性进行meta分析。方法计算机检索PubMed、Medline、Embase、维普、中国期刊全文数据库等数据库,收集培美曲塞联合铂类治疗非小细胞肺癌的随机对照试验,用Cochrane协作网提供的Revman4.2软件对数据进行Meta分析。结果 Meta分析显示,培美曲塞联合铂类(PP)与吉西他滨联合铂类(GP)在1年生存期OR=1.08,95%CI:0.91～1.29,P=0.38)上比较差异无统计学意义,但培美曲塞组的血液系统的不良反应(粒细胞减少、血小板减少、白细胞减少和贫血)相对减少,两组非血液系统的不良反应比较差异无统计学意义。结论与吉西他滨联合铂类相比,培美曲塞联合铂类治疗非小细胞肺癌与GP方案治疗生存期相似,但血液系统不良反应较轻。

Objective To observe the efficacy and toxicity of pemetrexed plus platinum versus gemcitabine plus platinum with advanced NSCLC.Methods Articles were selected from PubMed,Medline,Embase,VIP,CBM,CNKI,the Cochrane library.Meta-analysis was completed using software Review Manager 4.2.Results Meta analysis results suggested that：COMPARED with gecitabine plus platinum chemotherapy,pemetrexed plus platinum had no statistically significant benefit in 1-year survival rate,while Pemetrexed plus platinum had less hematologic toxicity.including：Neutropenia,Anemia,Thrombocytopenia,Leukopenia.The two chemotherapies were similar toxicity in non-hematology.Conclusion Pemetrexed plus platinum provides similar survival when compared with gecitabine plus platinum with less hematologic toxicity.